Yearly Archives: 2010

Dosing Initiated at Highest Planned Dose in Chronic Nerve Atrophy Patient Group

Fremont, CA October 20, 2010, – Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced it has dosed the first patient with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION) in its ongoing Phase I study […]

 FREMONT, CA., Aug. 18,2010  Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

Quark will receive […]

Nitto Denko to use its specialty delivery vehicle, targeting technology for fibrosis with novel therapeutic concepts together with Quark proprietary RNAi technology, novel structures with FTO and siRNA clinical development expertise to file for an IND for a new anti-fibrotic drug

Osaka, Japan and Fremont, CA, July 15, 2010 –  Nitto Denko Corporation, Japan’s leading diversified materials […]

FREMONT, Calif., Jun 28, 2010 –  Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced results from a second study of QPI-1007, a neuroprotective siRNA drug, in rat ocular hypertension model of glaucoma, conducted by Prof. Adriana Di Polo of the Department of Pathology and Cell Biology, Université de […]

FREMONT, Calif., Jun 24, 2010 –  Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that two of its siRNA drug candidates were featured in the following two presentations at the Glaucoma & Retinopathies 2010 conference, which was held June 21-22, 2010 in London, UK:

“QPI-1007, an ocular neuroprotective siRNA […]

FREMONT, Calif., Jun 15, 2010 –  Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that the European Commission has granted Orphan Medicinal Product Designation for QPI-1002 (also referred to as “I5NP”) for the prophylaxis of delayed graft function (DGF) in kidney transplant patients. QPI-1002 is a synthetic siRNA […]

FREMONT, Calif., Jun 10, 2010 –  Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the closing of a private financing by the existing investors of Quark totaling an aggregate of $10 million. The investors are funds of the prestigious SBI Holdings Group in Japan. In connection with the […]

FREMONT, Calif., May 17, 2010 –  Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today the publication of new insights on the role of its proprietary gene target, RTP801, in cigarette smoke-induced pulmonary injury and emphysema. Results are published in the June 2010 edition of Nature Medicine and online in […]

FREMONT, Calif., May 6, 2010 – Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that researchers from Pfizer, Inc. presented data on in vivo activity of PF-04523655 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 2-6, 2010 in Fort Lauderdale. PF-04523655 is a […]

FREMONT, Calif., May 4, 2010 – Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today the presentation of a poster at the 2010 American Transplant Congress titled, “A Nomogram for Predicting Risk of Delayed Graft Function Following Machine Perfusion of Renal Transplants.” The poster presents a new model developed by William […]